1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Wang, G.
Treleaven, W.D.
Cushley, R.J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
NE
Biochim.Biophys.Acta
BBACAQ
0113
0006-3002
1301
174
184
10.1016/0005-2760(96)00037-9
8664326
Conformation of human serum apolipoprotein A-I(166-185) in the presence of sodium dodecyl sulfate or dodecylphosphocholine by 1H-NMR and CD. Evidence for specific peptide-SDS interactions.
1996
10.2210/pdb1odp/pdb
pdb_00001odp
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
2336.605
APOA-I PEPTIDE
RESIDUES 166 - 185
1
man
polymer
APOA-I (166 - 185), APOLIPOPROTEIN A-I (166 - 185)
no
no
YSDELRQRLAARLEALKENG
YSDELRQRLAARLEALKENG
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
sample
9606
Homo sapiens
database_2
pdbx_database_status
pdbx_nmr_software
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
Other
1
0
1996-06-10
1
1
2008-03-24
1
2
2011-07-13
1
3
2022-02-23
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.process_site
_pdbx_nmr_software.name
Y
BNL
1996-03-02
REL
REL
MOST CLOSELY RESEMBLING THE AVERAGE STRUCTURE OF OF A CALCULATED SET OF 20 CONFORMERS
20
5
6.6
310
K
HAVEL
refinement
DGII
BIOSYM TECHNOLOGIES, INC.
refinement
Discover
TYR
1
n
1
TYR
1
A
SER
2
n
2
SER
2
A
ASP
3
n
3
ASP
3
A
GLU
4
n
4
GLU
4
A
LEU
5
n
5
LEU
5
A
ARG
6
n
6
ARG
6
A
GLN
7
n
7
GLN
7
A
ARG
8
n
8
ARG
8
A
LEU
9
n
9
LEU
9
A
ALA
10
n
10
ALA
10
A
ALA
11
n
11
ALA
11
A
ARG
12
n
12
ARG
12
A
LEU
13
n
13
LEU
13
A
GLU
14
n
14
GLU
14
A
ALA
15
n
15
ALA
15
A
LEU
16
n
16
LEU
16
A
LYS
17
n
17
LYS
17
A
GLU
18
n
18
GLU
18
A
ASN
19
n
19
ASN
19
A
GLY
20
n
20
GLY
20
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
-5.43
0.90
118.30
112.87
A
A
A
CB
CG
OD2
ASP
ASP
ASP
3
3
3
N
1
4.04
0.50
120.30
124.34
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
6
6
6
N
1
4.09
0.50
120.30
124.39
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
8
8
8
N
1
4.03
0.50
120.30
124.33
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
12
12
12
N
2
-5.42
0.90
118.30
112.88
A
A
A
CB
CG
OD1
ASP
ASP
ASP
3
3
3
N
2
4.09
0.50
120.30
124.39
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
6
6
6
N
2
4.11
0.50
120.30
124.41
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
8
8
8
N
2
4.06
0.50
120.30
124.36
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
12
12
12
N
3
4.04
0.50
120.30
124.34
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
6
6
6
N
3
4.11
0.50
120.30
124.41
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
8
8
8
N
3
3.97
0.50
120.30
124.27
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
12
12
12
N
4
-5.47
0.90
118.30
112.83
A
A
A
CB
CG
OD2
ASP
ASP
ASP
3
3
3
N
4
4.01
0.50
120.30
124.31
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
6
6
6
N
4
4.03
0.50
120.30
124.33
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
8
8
8
N
4
4.07
0.50
120.30
124.37
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
12
12
12
N
5
-5.44
0.90
118.30
112.86
A
A
A
CB
CG
OD2
ASP
ASP
ASP
3
3
3
N
5
4.01
0.50
120.30
124.31
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
6
6
6
N
5
4.11
0.50
120.30
124.41
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
8
8
8
N
5
4.04
0.50
120.30
124.34
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
12
12
12
N
1
A
A
CD
OE2
GLU
GLU
4
4
0.110
0.011
1.252
1.362
N
1
A
A
CD
OE2
GLU
GLU
14
14
0.110
0.011
1.252
1.362
N
1
A
A
CD
OE1
GLU
GLU
18
18
0.110
0.011
1.252
1.362
N
2
A
A
CD
OE2
GLU
GLU
4
4
0.111
0.011
1.252
1.363
N
2
A
A
CD
OE2
GLU
GLU
14
14
0.109
0.011
1.252
1.361
N
2
A
A
CD
OE2
GLU
GLU
18
18
0.109
0.011
1.252
1.361
N
3
A
A
CD
OE2
GLU
GLU
4
4
0.111
0.011
1.252
1.363
N
3
A
A
CD
OE2
GLU
GLU
14
14
0.109
0.011
1.252
1.361
N
3
A
A
CD
OE2
GLU
GLU
18
18
0.110
0.011
1.252
1.362
N
4
A
A
CD
OE2
GLU
GLU
4
4
0.109
0.011
1.252
1.361
N
4
A
A
CD
OE2
GLU
GLU
14
14
0.111
0.011
1.252
1.363
N
4
A
A
CD
OE1
GLU
GLU
18
18
0.110
0.011
1.252
1.362
N
5
A
A
CD
OE2
GLU
GLU
4
4
0.110
0.011
1.252
1.362
N
5
A
A
CD
OE2
GLU
GLU
14
14
0.110
0.011
1.252
1.362
N
5
A
A
CD
OE1
GLU
GLU
18
18
0.111
0.011
1.252
1.363
N
1
A
SER
2
70.54
123.92
1
A
GLU
18
-43.50
-81.83
1
A
ASN
19
-57.20
-75.15
2
A
SER
2
75.25
34.67
2
A
ASP
3
51.84
-90.46
2
A
GLU
18
-90.54
55.73
2
A
ASN
19
-167.27
-62.52
3
A
ASP
3
-27.59
-61.09
3
A
GLU
18
-46.59
-82.52
4
A
SER
2
-166.64
50.86
4
A
ASP
3
90.54
-75.90
4
A
ASN
19
-151.25
-74.40
5
A
SER
2
70.21
109.61
5
A
GLU
18
-46.64
-82.43
PEPTIDE OF HUMAN APOA-I RESIDUES 166-185. NMR, 5 STRUCTURES AT PH 6.6, 37 DEGREES CELSIUS AND PEPTIDE:SDS MOLE RATIO OF 1:40
1
Y
N
A
ASP
3
A
ASP
3
HELX_P
A
LYS
17
A
LYS
17
1
1
15
LIPID TRANSPORT
APOLIPOPROTEIN A-I, COFACTOR FOR LCAT ACTIVATION, LIPID TRANSPORT
APOA1_HUMAN
UNP
1
1
P02647
MKAAVLTLAVLFLTGSQARHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTST
FSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHE
LQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQ
GLLPVLESFKVSFLSALEEYTKKLNTQ
190
209
1ODP
1
20
P02647
A
1
1
20
1
P 1